Effectiveness of photobiomodulation in cancer patients with oral mucositis
- PDF / 210,806 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 49 Downloads / 215 Views
ORIGINAL ARTICLE
Effectiveness of photobiomodulation in cancer patients with oral mucositis Fernando Anschau 1,2,3
&
Jacqueline Webster 1 & Marcelo Eduardo Zanella Capra 1 & Airton Tetelbom Stein 1,4
Received: 17 February 2020 / Accepted: 8 October 2020 # Springer Nature Switzerland AG 2020
Abstract Introduction Mucositis occurs in more than 40% of chemotherapy-treated patients, significantly reducing their quality of life and increasing interventions for adequate analgesia and nutrition, as well as length of hospital stay. Many different interventions have been evaluated to reduce oral mucositis. Good results have recently been achieved with photobiomodulation (PBM), a technique that has practically no side effects. Objective The aim of this study was to evaluate the effectiveness of PBM in the treatment of oral mucositis in patients with leukemia or lymphoma at the Hospital Nossa Senhora da Conceição (HNSC). Method Accordingly, an observational retrospective cohort study was conducted with 60 patients with leukemia or lymphoma, comparing time for clinical improvement of oral mucositis in the groups with and without PBM. We included patients of both sexes, 18 years or older, admitted to the HNSC Hematology/Oncology Department from January 2015 to December 2017. Results The mean time to resolution of oral mucositis in the PBM-treated group was 7.1 ± 2.57 days and 14.1 ± 6.89 days in the group without PBM (p < 0.001). Conclusion PBM was shown to be more effective in reducing oral mucositis compared with the standard treatment protocol alone. Keywords Oral mucositis . Leukemia . Lymphoma . Photobiomodulation . Effectiveness
Introduction Mucositis is an inflammatory injury of the mucous membranes of the digestive tract caused by a number of anticancer therapies. Mucositis can present in various forms throughout the alimentary tract, from the oral to the gastrointestinal mucosa, usually characterized by a debilitating and devastating complication of cytotoxic therapies, very associated with
* Fernando Anschau [email protected] 1
Graduation Program on Evaluation and Production of Technologies for the Brazilian National Health System, Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande do Sul, Brazil
2
Escola de Medicina, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
3
Hospitalar Conceição Group, Av Francisco Trein 596, Porto Alegre, RS 9CEP:91350200, Brazil
4
Department of Public Health, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
those used for hematologic malignancies, where it is considered the most serious non-hematological complication in cancer treatment [1]. The incidence of grade 3 or 4 oral mucositis (OM), the most severe in accordance to the World Health Organization (WHO) [2], approaches 100% in patients receiving high doses of head and neck radiotherapy. Children with hematological malignancies undergoing chemotherapy have OM on average on the tenth day (± 6.8) of treatment in more than 50% of cas
Data Loading...
